ArticleFrontiers in neuroscience2018
Caffeine Protects Dopaminergic Neurons From Dopamine-Induced Neurodegeneration via Synergistic Adenosine-Dopamine D2-Like Receptor Interactions in Transgenic
Article in Frontiers in neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Genetic susceptibility to caffeine intake and metabolism: a systematic review.Journal of translational medicine · 2024Pooled it
- Does glitazone treatment have a role on the prevention of Parkinson's disease in adult diabetic population? A systematic review.Metabolic brain disease · 2020Pooled it
- Cognitive enhancement: Effects of methylphenidate, modafinil, and caffeine on latent memory and resting state functional connectivity in healthy adults.Human brain mapping · 2022Trial
- Dissecting GPCR Contributions to Gαo-Dependent Motor Dysfunction inBiomedicines · 2026Article
- Sex-specific effects of chronic caffeine on impulsive choice and serotonergic markers in an ADHD rat model.Psychopharmacology · 2026Article
- Longitudinal assessment of the association between pesticide exposure and lifestyle with Parkinson's disease motor severity.NPJ Parkinson's disease · 2025Article
- Pharmacological effects and phytochemical profile of methanolicFrontiers in pharmacology · 2025Article
- Metabolomic profiling uncovers diagnostic biomarkers and dysregulated pathways in Parkinson's disease.Frontiers in neurology · 2025Article
- Epidemiology of Parkinson's Disease: An Update.Current neurology and neuroscience reports · 2024Review
- Gene regulation in activated microglia by adenosine APurinergic signalling · 2024Article
- Effect of altered production and storage of dopamine on development and behavior inFrontiers in toxicology · 2024Article
- Overview of Caffeine Effects on Human Health and Emerging Delivery Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Comparative and Combined Effects of Epigallocatechin-3-gallate and Caffeine in Reducing Lipid Accumulation in Caenorhabditis elegans.Plant foods for human nutrition (Dordrecht, Netherlands) · 2022Article
- Using aPharmaceuticals (Basel, Switzerland) · 2022Article
- Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia.Human molecular genetics · 2022Article
- Haloperidol Interactions with the dop-3 Receptor in Caenorhabditis elegans.Molecular neurobiology · 2021Article
- Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain-Gut Axis.Nutrients · 2020Review
- Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenicPharmaceutical biology · 2020Article
- Maternal Caffeine Intake Disrupts Eggshell Integrity and Retards Larval Development by Reducing Yolk Production in aNutrients · 2020Article
- Caffeine induces neurobehavioral effects through modulating neurotransmitters.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have suggested that caffeine reduces the risk of L-DOPA-induced dyskinesia. However, caffeine is also known to promote dopamine signaling, which seemingly contradicts this observed effect. To this end, the study aimed to clarify the mechanism of caffeine neuroprotection
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.